Robert Kapito - IShares Medical Trustee
| IHI Etf | USD 60.35 0.05 0.08% |
Mr. Robert S. Kapito serves as Trustee of Ishares Dow Jones US Medical Devices Index Fund since 2009. Mr. Kapito has served as a Director of iShares, Inc. since 2009, a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010 and a Director of BlackRock, Inc. since 2007. In addition, he has over 20 years of experience as part of BlackRock, Inc. and BlackRocks predecessor entities. Mr. Kapito serves as President and Director of BlackRock, Inc., and is the Chairman of the Operating Committee, a member of the Office of the Chairman, the Leadership Committee and the Corporationrationrate Council. He is responsible for daytoday oversight of BlackRocks key operating units, including the Account Management and Portfolio Management Groups, Real Estate Group and BlackRock Solutions. Prior to assuming his current responsibilities in 2007, Mr. Kapito served as Head of BlackRocks Portfolio Management Group. In that role, he was responsible for overseeing all portfolio management within BlackRock, including the Fixed Income, Equity, Liquidity, and Alternative Investment Groups. Mr. Kapito serves as a member of the Board of Trustees of the University of Pennsylvania. He is also President of the Board of Directors for the Hope Heroes Childrens Cancer Fund since 2002 and President of the Board of Directors for Periwinkle Theatre for Youth, a national nonprofit artsin education organization, since 1983
| Age | 62 |
| Tenure | 15 years |
| Professional Marks | MBA |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Medical Equipment Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 4.92 Billion |
| Average Trading Valume | 478,081.5 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Charles Hurty | iShares Pharmaceuticals ETF | 72 | |
| Charles Hurty | iShares Expanded Tech Software | 72 | |
| John Martinez | iShares Healthcare ETF | 55 | |
| John Kerrigan | iShares Expanded Tech Software | 60 | |
| John Kerrigan | iShares Aerospace Defense | 60 | |
| Madhav Rajan | iShares Healthcare ETF | 52 | |
| Cecilia Herbert | iShares Aerospace Defense | 67 | |
| Eilleen Clavere | iShares Pharmaceuticals ETF | 60 | |
| Madhav Rajan | iShares Expanded Tech Software | 52 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Eilleen Clavere | iShares Aerospace Defense | 60 | |
| John Martinez | iShares Aerospace Defense | 55 | |
| John Kerrigan | iShares Pharmaceuticals ETF | 60 | |
| John Martinez | iShares Pharmaceuticals ETF | 55 | |
| Robert Silver | iShares Healthcare ETF | 57 | |
| Cecilia Herbert | iShares Expanded Tech Software | 67 | |
| Charles Hurty | iShares Healthcare ETF | 72 | |
| Eilleen Clavere | iShares Healthcare ETF | 60 | |
| Robert Silver | iShares Expanded Tech Software | 57 | |
| Madhav Rajan | iShares Pharmaceuticals ETF | 52 | |
| Cecilia Herbert | iShares Pharmaceuticals ETF | 67 | |
iShares Medical Devices Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 24.14 X | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 3.38 X | |||
| Number Of Employees | 15 | |||
| Beta | 1.04 | |||
| Total Asset | 5.79 B | |||
| One Year Return | 22.20 % | |||
| Three Year Return | (2.00) % | |||
| Five Year Return | 7.50 % | |||
| Ten Year Return | 13.10 % |
Currently Active Assets on Macroaxis
When determining whether iShares Medical Devices offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Medical Devices Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Medical Devices Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Medical Devices. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
The market value of iShares Medical Devices is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Medical's value that differs from its market value or its book value, called intrinsic value, which is IShares Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Medical's market value can be influenced by many factors that don't directly affect IShares Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.